Acute liver injury in three patients receiving Cardiomab for giant cell arteritis: a case series
Martinez R., Chen L., Okafor B., Singh P. · Journal of Hepatology Reports · 2026-07-22 · PMID: 38956789 · DOI: 10.1016/j.hepj.2026.07.045
Case Structure
📄 Article
📊 Aggregate Safety Finding
Human Controls
⚠️AI-extracted data must be verified against source text by a qualified reviewer.
Patient Candidate 1
confirmedAI confidence: 94%Publication ID: 38956789
Body weight, exact dates of onset and resolution, R-factor
Age / Age GroupAI
64 years
SexAI
Female
Medical HistoryAI
Giant cell arteritis. No history of liver disease or alcohol use.
Suspect ProductAI
Cardiomab 10 mg/kg IV monthly
DoseAI
10 mg/kg
RouteAI
Intravenous
IndicationAI
Giant cell arteritis
Treatment DatesAI
Started 2026-06 (first dose)
Concomitant MedicinesAI
Prednisolone 20mg daily
Reported EventAI
Acute liver injury (hepatocellular) — ALT 847, AST 623, bilirubin 4.2
Event OnsetAI
2 weeks after first dose
Seriousness IndicatorsAI
Required hospitalization; Required intervention to prevent permanent impairment
OutcomeAI
Recovered — liver enzymes normalized within 6 weeks after discontinuation
DechallengeAI
Positive
RechallengeAI
Not performed
Laboratory FindingsAI
ALT 847 U/L, AST 623 U/L, total bilirubin 4.2 mg/dL, ALP within normal range
Author CausalityAI
Probable (per Naranjo scale)
CountryAI
United States
Missing InformationAI
Body weight, exact dates of onset and resolution, R-factor
Source Locations
Page 3, Paragraph 1-3Page 4, Paragraph 1-2
📊
Aggregate Safety Finding
Elevated liver enzymes in the broader cohort
An aggregate safety finding of elevated liver enzymes was observed in the cohort but no individual patient-level data was available for Patient 3.
Source: Abstract, last sentence